CTLA4 and nonpapillary renal cell carcinoma: Currently, immunotherapies such as programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors have been approved for managing ccRCC (3).